Balapiravir

Cat. No.: HY-10443
CAS No.: 690270-29-2
Molecular Formula: C₂₁H₃₀N₆O₈
Molecular Weight: 494.5
Target: HCV
Pathway: Anti-infection
Storage:
- Powder: -20°C, 3 years; 4°C, 2 years
- In solvent: -80°C, 6 months; -20°C, 1 month

Solvent & Solubility

In Vitro
DMSO: ≥ 100 mg/mL (202.22 mM)
* “≥” means soluble, but saturation unknown.

Preparing Stock Solutions

<table>
<thead>
<tr>
<th>Concentration</th>
<th>1 mg</th>
<th>5 mg</th>
<th>10 mg</th>
</tr>
</thead>
<tbody>
<tr>
<td>1 mM</td>
<td>2.0222 mL</td>
<td>10.1112 mL</td>
<td>20.2224 mL</td>
</tr>
<tr>
<td>5 mM</td>
<td>0.4044 mL</td>
<td>2.0222 mL</td>
<td>4.0445 mL</td>
</tr>
<tr>
<td>10 mM</td>
<td>0.2022 mL</td>
<td>1.0111 mL</td>
<td>2.0222 mL</td>
</tr>
</tbody>
</table>

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description
Balapiravir (R1626, Ro 4588161) is the prodrug of a nucleoside analogue inhibitor of the hepatitis C virus (HCV) RNA-dependent RNA polymerase (R1479, RG1479). IC50 Value: Target: HCV
Balapiravir (R-1626; R 1626; Ro 4588161) is useful for Anti HCV. Balapiravir (R1626) is the tri-isobutyrate ester prodrug of R1479 under clinical development to improve exposure of R1479 upon oral administration. Balapiravir was discontinued for safety reasons in 28-36% of patients (most often for lymphopenia) and the percentage of patients with serious adverse events (especially hematological, infection, ocular events) was dose related. Serious hematological adverse events (particularly neutropenia, lymphopenia) were more common in balapiravir recipients. Two deaths in the balapiravir/peginterferon alfa-2a/ribavirin combination groups were considered possibly related to study medication.

CUSTOMER VALIDATION
REFERENCES


Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA